Germany Nuclear Medicine Market Size & Outlook, 2026-2033
Global Market
Related Markets
Germany nuclear medicine market highlights
- The Germany nuclear medicine market generated a revenue of USD 1,025.3 million in 2025 and is expected to reach USD 1,646.4 million by 2033.
- The Germany market is expected to grow at a CAGR of 5.3% from 2026 to 2033.
- In terms of segment, diagnostics was the largest revenue generating product in 2025.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
Nuclear medicine market data book summary
| Market revenue in 2025 | USD 1,025.3 million |
| Market revenue in 2033 | USD 1,646.4 million |
| Growth rate | 5.3% (CAGR from 2026 to 2033) |
| Largest segment | Diagnostics |
| Fastest growing segment | Diagnostics |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
Other key industry trends
- In terms of revenue, Germany accounted for 4.8% of the global nuclear medicine market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, France nuclear medicine market is projected to lead the regional market in terms of revenue in 2033.
- France is the fastest growing regional market in Europe and is projected to reach USD 1,853.9 million by 2033.
Germany accounts for the largest share in Europe’s radiopharmaceuticals market. The country operates seven research reactors for the R&D of medical isotopes. Increasing investments in the development of nuclear medicine and rising healthcare expenditure are expected to contribute to the growth of the nuclear medicine market during the forecast period.
The federal government and other investors in Germany provide financial support for R&D activities related to 99Mo production. According to the International Atomic Energy Agency, in April 2019, Germany was committed toward strengthening its safety and enhancing its nuclear reactors.
For instance, in June 2020, ITM (ITM Isotope Technologies München AG) entered into two supply agreement with POINT Biopharma, Inc. for Endolucin Beta/no carrier-added (n.c.a) Lutetium-177 (177Lu) chloride, to help with clinical & commercial supply of PNT2002 (a 177Lu-PSMA radiopharmaceutical) to treat prostate cancer.
No credit card required*
Publish Date: Jun 17, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Nuclear Medicine Market Scope
Nuclear Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| GE HealthCare Technologies Inc Common Stock | View profile | 51,000 | 500 West Monroe Street, Chicago, IL, United States, 60661 | www.gehealthcare.com |
| Cardinal Health Inc | View profile | 48,000 | 7000 Cardinal Place, Dublin, OH, United States, 43017 | www.cardinalhealth.com |
| Mallinckrodt PLC Ordinary Shares - New | View profile | 2,700 | College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, Ireland, 15 | www.mallinckrodt.com |
| Eckert & Ziegler Bebig SA | View profile | 501-1000 | Seneffe, Hainaut, Belgium, Europe | www.ezag.com/home/ |
| Nordion | View profile | 251-500 | Kanata, Ontario, Canada, North America | nordion.com |
| Bracco | View profile | 1001-5000 | Milan, Lombardia, Italy, Europe | www.bracco.com |
| Lantheus Holdings Inc | View profile | 834 | 201 Burlington Road, South Building, Bedford, MA, United States, 01730 | www.lantheus.com |
| Jubilant Pharmova | View profile | 10001+ | Noida, Uttar Pradesh, India, Asia | www.jubilantpharmova.com |
| Iren SpA | View profile | 10,000 | Via Nubi di Magellano, 30, Reggio Emilia, Italy, 42123 | www.gruppoiren.it |
| Abliva AB | View profile | 6 | Scheeletorget 1, Medicon Village, Lund, Sweden, 223 81 | www.abliva.com |
Germany Nuclear Medicine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Nuclear Medicine Market Outlook will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 86.18% in 2025.
Horizon Databook has segmented the Germany nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2021 to 2033.
Germany accounts for the largest share in Europe’s radiopharmaceuticals market. The country operates seven research reactors for the R&D of medical isotopes. Increasing investments in the development of nuclear medicine and rising healthcare expenditure are expected to contribute to the growth of the nuclear medicine market during the forecast period.
The federal government and other investors in Germany provide financial support for R&D activities related to 99Mo production. According to the International Atomic Energy Agency, in April 2019, Germany was committed toward strengthening its safety and enhancing its nuclear reactors.
For instance, in June 2020, ITM (ITM Isotope Technologies München AG) entered into two supply agreement with POINT Biopharma, Inc. for Endolucin Beta/no carrier-added (n.c.a) Lutetium-177 (177Lu) chloride, to help with clinical & commercial supply of PNT2002 (a 177Lu-PSMA radiopharmaceutical) to treat prostate cancer.
- Germany Nuclear Medicine Market Product Outlook (Revenue, USD Million , 2021-2033)
- Diagnostics
- Therapeutics
- Germany Nuclear Medicine Market Application Outlook (Revenue, USD Million , 2021-2033)
- Cardiology
- Neurology
- Oncology
- Thyroid
- Lymphoma
- Bone Metastasis
- Endocrine Tumor
- Pulmonary Scans
- Urology
- Other
- Germany Nuclear Medicine Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals
- Diagnostic Centers
- Others
Reasons to subscribe to Nuclear Medicine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Nuclear Medicine Market Outlook databook
- Our clientele includes a mix of Nuclear Medicine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany Nuclear Medicine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Germany Nuclear Medicine Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Germany Nuclear Medicine Market, 2021-2033 (US$M)
Germany nuclear medicine market statistics, by product, 2021-2033 (US$M)
